Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Pharmacia integration

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Senior VP-Strategic Planning & Business Development Tom Booth will lead Consumer Healthcare division's transition team in the Pharmacia integration. Teams are responsible for "day-to-day transition planning process," serving as "focal point for two-way communication between the divisions and corporate and between the divisions themselves," says 1Pfizer employee newsletter article filed with SEC. Pfizer, Pharmacia team leaders will meet for first time Aug. 13. "Transition process will be carried out using Pfizer's existing governance structure, which went through a significant overhaul following the W-L merger, with more decision-making authority and accountability being given to the businesses," Pfizer says. Companies expect deal to close by year-end (2"The Tan Sheet" July 22, 2002, p. 8)...

Pfizer Senior VP-Strategic Planning & Business Development Tom Booth will lead Consumer Healthcare division's transition team in the Pharmacia integration. Teams are responsible for "day-to-day transition planning process," serving as "focal point for two-way communication between the divisions and corporate and between the divisions themselves," says 1 Pfizer employee newsletter article filed with SEC. Pfizer, Pharmacia team leaders will meet for first time Aug. 13. "Transition process will be carried out using Pfizer's existing governance structure, which went through a significant overhaul following the W-L merger, with more decision-making authority and accountability being given to the businesses," Pfizer says. Companies expect deal to close by year-end (2 (Also see "Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy" - Pink Sheet, 22 Jul, 2002.), p. 8)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel